A maximum-severity vulnerability in the popular n8n automation platform lets anyone on the network take over servers without a login. The flaw, dubbed “ni8mare,” is a centralization nightmare for enterprises.
Solana Mobile is launching a new token, SKR, to support its open mobile platform centered on the Seeker smartphone. The fixed supply of 10 billion tokens will be used for staking and governance, managed by a group called Guardians starting in 2026.
Constellation Energy has finalized its massive acquisition of power generator Calpine. The deal, valued at $26.6 billion including debt, creates a U.S. electricity behemoth with a huge mix of nuclear and natural gas assets. It’s a direct bet on skyrocketing power demand from data centers.
A joint venture led by Italian cable giant Prysmian has agreed to buy subsea telecom systems provider Xtera. The deal, valued at $65 million, is expected to close in early 2026 and signals a major push into the AI-driven cable market.
Spotify is doubling down on social features within its app. The new “Listening Activity” shows friends what you’re streaming in real time, while “Request to Jam” lets Premium users invite others to a collaborative listening session. Both features are rolling out now via the Messages system.
A pro-Russian hacktivist group is coordinating sustained denial-of-service attacks using a volunteer botnet. Their tool, DDoSia, allows anyone to join in, turning geopolitical tension into disruptive cyber campaigns. It’s more about persistent harassment than outright destruction.
Logitech’s configuration software for Mac broke after the company let a critical security certificate expire. The company has released a manual patch, calling the oversight an “inexcusable mistake.”
Meta’s planned $2 billion acquisition of AI startup Manus is facing a review by Chinese regulators. The concern is whether the deal violates the country’s technology export controls, even though Manus has since moved to Singapore.
In a major move for precision oncology, Amgen is acquiring UK biotech Dark Blue Therapeutics. The deal, valued at up to €718 million, centers on a promising leukemia drug candidate currently in pre-clinical studies.
Investment firm Baird has upgraded chemical manufacturer Albemarle to ‘outperform’ from ‘neutral’. Analyst Ben Kallo nearly doubled his price target to $210, implying a potential 33% upside from current levels.
